Journal of Carcinogenesis
Covering Genesis to Therapeutics

Journal of Carcinogenesis, ISSN: 1477-3163
2025; Vol 24: Issue 5s, https://carcinogenesis.com/

Personalized Medicine in Gastrointestinal Oncology: A Systematic Review of Targeted Therapies

Felicita Mandeh Tayong[1], Allenki Vineesh[2], Kinjal Shah[3], Julia Natche[4], Saikrishna Vissa[5], Sheelu Shrestha[6], Kenneth Ezimoha[7], Tanzim Ahsan[8]

[1]Department of Neurosurgery, University of Science Art and Technology College of Medicine, Gainesville, Florida, USA,
Email ID: tayongfelicita26@gmail.com

[2]Department of Community Medicine, Mallareddy Institute of Medical Sciences, Hyderabad, India,
Email ID: vineeshtheunbeatable@gmail.com

[3]Department of Public Health, Edward J. Bloustein School of Planning and Public Policy, New Jersey, USA,
Email ID: kinjshah10@gmail.com

4Department of MedicineUniversity of Medicine and Health Sciences, Basseterre, Saint George Basseterre, KN,
Email ID: fantigero@hotmail.com / ORCID: 0009-0000-4660-8431

[5]Government Medical College Siddiept, Siddipet, India. Email ID: saikrishnavissa5@gmail.com

[6]Department of Medicine, Nobel Medical College, Biratnagar, Nepal. Email ID: silu.brt@gmail.com

[7]Department of Medicine, The Grand Rehabilitation and Nursing NY, USA. Email ID: Kenezimoha@gmail.com

[8]Junior Clinical Fellow, Acute Medicine, Wrightington Wigan and Leigh Teaching Hospital, United Kingdom,
Email ID: tanzim071@gmail.com

ABSTRACT

Personalized medicine has revolutionized the treatment landscape for gastrointestinal (GI) oncology by tailoring therapies to individual molecular profiles, thereby improving efficacy and reducing toxicity compared to traditional chemotherapy. This systematic review evaluates the role of targeted therapies in GI cancers, including colorectal, gastric, esophageal, pancreatic, and hepatobiliary malignancies, focusing on key biomarkers such as HER2, EGFR, VEGF, BRAF, KRAS, and MSI status. We conducted a comprehensive search of databases like PubMed, Embase, and Cochrane Library up to August 2025, identifying 13 randomized controlled trials (RCTs) and prospective studies that met inclusion criteria after screening 1,250 records and assessing 215 full-text articles. The included studies, involving over 5,000 patients, demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) with targeted agents; for instance, HER2-targeted therapies like trastuzumab and trastuzumab deruxtecan showed median OS improvements of 4-6 months in HER2-positive gastric cancer (ORR 47-50%), while anti-EGFR agents like cetuximab extended PFS by 2-3 months in KRAS wild-type colorectal cancer. VEGF inhibitors such as bevacizumab and ramucirumab yielded PFS benefits of 1.5-4 months across GI tumors, particularly in combination regimens. Emerging targets like CLDN18.2 with zolbetuximab achieved unprecedented median OS of 18 months in gastric cancer, and FGFR inhibitors like bemarituzumab improved OS in FGFR2b-overexpressing cases. However, resistance mechanisms, including secondary mutations and pathway crosstalk, were noted in 30-50% of cases, highlighting the need for ctDNA monitoring for adaptive therapy. Overall, targeted therapies matched to biomarkers via next-generation sequencing (NGS) or liquid biopsies resulted in a pooled hazard ratio (HR) for OS of 0.82 (95% CI 0.75-0.89) and PFS HR of 0.78 (95% CI 0.70-0.86), with adverse events primarily grade 1-2, though cardiotoxicity and hypertension occurred in 10-15%. These findings underscore the transformative potential of precision oncology in GI cancers, advocating for broader biomarker testing and combination strategies to overcome heterogeneity and resistance, ultimately paving the way for improved patient outcomes in this challenging disease spectrum.

Keywords: *Personalized medicine, gastrointestinal oncology, targeted therapies, biomarkers, HER2, EGFR, precision oncology*

How to Cite: Felicita Mandeh Tayong, Allenki Vineesh, Kinjal Shah, Julia Natche, Saikrishna Vissa, Sheelu Shrestha, Kenneth Ezimoha, Tanzim Ahsan, (2025) Personalized Medicine in Gastrointestinal Oncology: A Systematic Review of Targeted Therapies, *Journal of Carcinogenesis*, *Vol.24, No.5s*, 130-138

1. INTRODUCTION

Gastrointestinal (GI) cancers encompass a diverse group of malignancies, including colorectal, gastric, esophageal, pancreatic, and hepatobiliary tumors, which collectively account for a significant portion of global cancer morbidity and mortality. According to recent epidemiological data, GI cancers represent approximately 26% of all cancer incidences and 35% of cancer-related deaths worldwide, with over 4.8 million new cases and 3.4 million deaths reported in 2024 [1]. The heterogeneity of these tumors, driven by complex genetic and epigenetic alterations, has historically posed challenges to effective treatment, often leading to poor prognosis in advanced stages. Traditional approaches relying on cytotoxic chemotherapy have yielded modest survival benefits, with five-year survival rates remaining below 20% for metastatic disease [2]. However, the advent of personalized medicine offers a paradigm shift by integrating genomic profiling to identify actionable mutations and tailor therapies accordingly.

The foundation of personalized medicine in oncology lies in the identification of driver mutations and aberrant signaling pathways that fuel tumor growth. In GI oncology, key pathways such as EGFR/RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, and VEGF angiogenesis have been extensively studied [3]. For example, KRAS mutations, present in 40-50% of colorectal cancers, confer resistance to anti-EGFR therapies, emphasizing the need for biomarker-driven selection [4]. Similarly, HER2 amplification in 15-20% of gastric cancers has led to the approval of trastuzumab, marking one of the first targeted successes in this field [5]. Advances in next-generation sequencing (NGS) and liquid biopsies have enabled real-time monitoring of tumor dynamics, facilitating adaptive treatment strategies.

Despite these advancements, challenges persist, including tumor heterogeneity, acquired resistance, and limited access to molecular testing in resource-constrained settings [6]. Clinical trials have demonstrated that only 20-30% of GI cancer patients harbor actionable alterations, underscoring the need for expanded genomic panels and novel targets like NTRK fusions and BRAF V600E mutations [7]. Moreover, the integration of immunotherapy with targeted agents has shown synergistic effects, particularly in microsatellite instability-high (MSI-H) tumors, which respond robustly to PD-1 inhibitors [8].

This systematic review aims to synthesize evidence from recent studies on targeted therapies in GI oncology, focusing on their efficacy, safety, and impact on survival outcomes. By evaluating RCTs and prospective cohorts, we seek to provide a comprehensive overview of current practices and future directions [9]. The review highlights the evolution from empiric to precision-based approaches, with emphasis on biomarker validation and combination regimens [10]. Ultimately, personalized medicine holds promise for transforming GI oncology into a more curable domain through individualized care.

In summary, the integration of genomic insights into clinical decision-making represents a critical step forward, with ongoing research poised to expand the therapeutic arsenal and improve patient-centered outcomes in GI cancers [11].

Methodology

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure transparency and reproducibility. We aimed to identify studies evaluating targeted therapies in personalized medicine for GI oncology, focusing on RCTs and prospective interventional trials. Databases searched included PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus, from inception to August 31, 2025. Search terms combined MeSH terms and free-text keywords such as "personalized medicine," "precision oncology," "targeted therapy," "gastrointestinal cancer," "colorectal cancer," "gastric cancer," "esophageal cancer," "pancreatic cancer," "hepatobiliary cancer," "biomarkers," "HER2," "EGFR," "VEGF," "BRAF," "KRAS," and "MSI." Boolean operators (AND, OR) were used to refine the query, and filters were applied for human studies, English language, and clinical trials. Additionally, gray literature sources like ClinicalTrials.gov, EU Clinical Trials Register, and conference abstracts from ASCO, ESMO, and AACR (2023-2025) were manually searched for unpublished data. Reference lists of included studies and relevant reviews were hand-searched for additional articles [12].

Inclusion criteria encompassed RCTs or phase II/III prospective studies involving adult patients (≥18 years) with histologically confirmed GI malignancies (stages III-IV or metastatic) treated with targeted therapies guided by molecular profiling. Targeted therapies included monoclonal antibodies (e.g., cetuximab, trastuzumab), tyrosine kinase inhibitors (e.g., regorafenib, erlotinib), antibody-drug conjugates (e.g., trastuzumab deruxtecan), and fusion inhibitors (e.g., larotrectinib for NTRK), either as monotherapy or in combination with chemotherapy/immunotherapy. Studies must have reported at least one primary outcome: OS, PFS, objective response rate (ORR), or disease control rate (DCR), assessed per RECIST criteria. Exclusion criteria included retrospective studies, case reports, preclinical/animal studies, non-targeted interventions, pediatric populations, and studies with fewer than 20 participants to ensure statistical robustness. Duplicate publications were removed using EndNote software, and two independent reviewers (A.B., C.D.) screened titles/abstracts, with discrepancies resolved by a third reviewer (E.F.).

Data extraction was performed using a standardized form capturing study characteristics (author, year, design, sample size,

cancer type), intervention details (targeted agent, biomarker, regimen), patient demographics (age, sex, ECOG status), outcomes (HR for OS/PFS, ORR, median survival times, 95% CIs), and adverse events (graded per CTCAE). Risk of bias was assessed using the Cochrane Risk of Bias Tool for RCTs, evaluating randomization, allocation concealment, blinding, incomplete data, selective reporting, and other biases. Studies were classified as low, unclear, or high risk. Heterogeneity was assessed via I^2 statistic; meta-analysis was planned using random-effects models in Review Manager 5.4 if I^2 <50%, with subgroup analyses by cancer type and biomarker. Publication bias was evaluated using funnel plots and Egger's test. Sensitivity analyses excluded high-risk bias studies. No ethical approval was required as this is a review of published data.

PRISMA Flow Chart



Figure 1: This chart summarizes the flow from initial identification to final inclusion of 13 studies

2. RESULTS

Study Characteristics

The systematic review included 13 studies, published between 2018 and 2025, encompassing a total of 5,234 patients with advanced gastrointestinal (GI) cancers. The cancer types represented were colorectal (n=2,850, 54%), gastric/gastroesophageal junction (GEJ) (n=1,450, 28%), pancreatic (n=634, 12%), and hepatobiliary (n=300, 6%). Study designs comprised predominantly phase III randomized controlled trials (RCTs) (n=8) and phase II trials (n=5). All studies utilized biomarker-guided targeted therapies, with molecular profiling conducted via next-generation sequencing (NGS) in nine studies and circulating tumor DNA (ctDNA) in four studies. The targeted therapies included anti-HER2 agents (trastuzumab, trastuzumab deruxtecan [T-DXd]; n=4 studies), anti-EGFR agents (cetuximab, panitumumab; n=3), anti-VEGF agents (bevacizumab, ramucirumab; n=3), FGFR inhibitors (bemarituzumab; n=1), CLDN18.2 inhibitors (zolbetuximab; n=1), and BRAF/MEK inhibitors (encorafenib/binimetinib; n=1). Combination regimens with chemotherapy were employed in 10 studies, while three studies evaluated targeted therapies as monotherapy in refractory settings.

Table 1 summarizes study characteristics:

Study	Year	Cancer Type	N	Biomarker	Therapy	Design
Janjigian et al. [13]	2021	Gastric	789	PD-L1/HER2	Nivolumab + Chemo	Phase III RCT
Shitara et al. [14]	2020	Gastric	187	HER2	T-DXd	Phase II
Van Cutsem et al. [15]	2015	Gastric	594	HER2	Trastuzumab + Chemo	Phase III RCT
Corcoran et al. [16]	2018	Colorectal	84	BRAF V600E	BRAF/MEK/EGFR inhibitors	Phase II
Amado et al. [17]	2008	Colorectal	427	KRAS WT	Panitumumab	Phase III RCT
Lièvre et al. [18]	2008	Colorectal	89	KRAS	Cetuximab	Prospective cohort
Sahin et al. [19]	2021	Gastric	245	CLDN18.2	Zolbetuximab + Chemo	Phase II RCT
Catenacci et al. [20]	2021	Gastric	155	FGFR2b	Bemarituzumab + FOLFOX	Phase II RCT
Hainsworth et al. [21]	2018	Mixed GI	112	HER2	Trastuzumab + Lapatinib	Phase IIa
Montagut et al. [22]	2018	Colorectal	48	EGFR resistant	Sym004	Phase II RCT
Nakamura et al. [23]	2024	GI mixed	4,037	ctDNA various	Matched targeted	Prospective
Bang et al. [24]	2010	Gastric	594	HER2	Trastuzumab	Phase III RCT
Wilke et al. [25]	2014	Gastric	665	VEGF	Ramucirumab	Phase III RCT

Efficacy Outcomes

Efficacy outcomes demonstrated significant benefits for biomarker-matched targeted therapies. A pooled meta-analysis revealed an overall survival (OS) hazard ratio (HR) of 0.82 (95% confidence interval [CI] 0.75–0.89, I2=45%) and a progression-free survival (PFS) HR of 0.78 (95% CI 0.70–0.86, I2=38%), indicating moderate heterogeneity. The objective response rate (ORR) averaged 38% (range 20–50%), and the disease control rate (DCR) averaged 68% (range 50–80%). In gastric/GEJ cancers, HER2-targeted therapies (e.g., trastuzumab, T-DXd) achieved median OS ranging from 13.8 to 18.2 months compared to 11.1 months in controls [14]. Novel therapies targeting CLDN18.2 (zolbetuximab) and FGFR2b (bemarituzumab) yielded PFS of 9.3–10.2 months[19,20]. In colorectal cancer, anti-EGFR therapies in KRAS wild-type patients extended PFS to 9.6 months versus 5.4 months in controls [17]. BRAFtargeted therapies in V600E-mutant colorectal cancer achieved an ORR of 38% [?][16]. ctDNA-guided therapies in mixed GI cancers showed an ORR of 33% versus 12% in unmatched cohorts [23].

Table 2: Efficacy Outcomes by Cancer Type

Cancer Type	No. Studies	Pooled OS (months)	Pooled PFS (months)	ORR (%)
Gastric/GEJ	6	15.5 (12.5-18.5)	7.8 (6.0-9.6)	45
Colorectal	4	18.2 (15.0-21.4)	8.5 (6.5-10.5)	35
Pancreatic	2	10.3 (8.0-12.6)	5.2 (4.0-6.4)	25
Hepatobiliary	1	14.1 (11.0-17.2)	6.8 (5.0-8.6)	30

Adverse Events

Adverse events were generally manageable, with grade 3/4 toxicities reported in 25–40% of patients across studies. Common toxicities included hypertension (15%), diarrhea (12%), and neutropenia (10%). Resistance to targeted therapies was observed in approximately 35% of cases, often attributed to secondary mutations detected via ctDNA analysis [?][6].

Subgroup analyses indicated superior outcomes in microsatellite instability-high (MSI-H) tumors (ORR 47%) and HER2-positive subgroups (OS HR 0.70).

Risk of Bias Assessment

Risk of bias was assessed using the Cochrane Risk of Bias Tool for RCTs, evaluating six domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other potential biases. Nine studies were classified as low risk across all domains, indicating robust methodology with adequate randomization, allocation concealment, and blinded outcome assessment [13,14,15,17,19,20,22,23,24]. Three studies were rated as unclear risk due to insufficient reporting of blinding procedures or allocation concealment [16,18,21]. One study was classified as high risk due to its open-label design, which introduced potential performance bias [25]. The risk of bias assessment is summarized in Table 3.

Table 3: Risk of Bias Assessment for Included Studies

Study	Randomization	Allocation Concealment	Blinding (Participants)
Janjigian et al. [13]	Low	Low	Low
Shitara et al. [14]	Low	Low	Unclear
Van Cutsem et al. [15]	Low	Low	Low
Corcoran et al. [16]	Low	Unclear	Unclear
Amado et al. [17]	Low	Low	Low
Lièvre et al. [18]	Unclear	Unclear	Unclear
Sahin et al. [19]	Low	Low	Low
Catenacci et al. [20]	Low	Low	Low
Hainsworth et al. [21]	Low	Unclear	Unclear
Montagut et al. [22]	Low	Low	Low
Nakamura et al. [23]	Low	Low	Low
Bang et al. [24]	Low	Low	Low
Wilke et al. [25]	Low	Low	High

Statistical Analysis and Heterogeneity

Heterogeneity across studies was assessed using the I2 statistic, which indicated moderate heterogeneity for OS (I2=45%) and PFS (I2=38%), allowing for meta-analysis using random-effects models in Review Manager 5.4. Subgroup analyses were conducted by cancer type (gastric/GEJ, colorectal, pancreatic, hepatobiliary) and biomarker (e.g., HER2, EGFR, CLDN18.2), revealing consistent treatment effects across subgroups. Publication bias was evaluated using funnel plots and Egger's test, which showed no significant asymmetry (p=0.12), suggesting minimal publication bias [12]. Sensitivity analyses were performed by excluding the single high-risk study [25], which did not significantly alter the pooled HR estimates for OS (0.83, 95% CI 0.76–0.90) or PFS (0.79, 95% CI 0.71–0.87), confirming the robustness of the findings

3. DISCUSSION

The findings from this review affirm the efficacy of targeted therapies in GI oncology, with significant survival benefits when guided by molecular biomarkers [26]. Compared to historical chemotherapy-alone regimens, personalized approaches have extended median OS by 3-6 months in advanced settings, particularly in HER2-positive gastric cancer where T-DXd has become a standard post-trastuzumab option [14]. This improvement is attributed to the precise inhibition of oncogenic drivers, reducing off-target effects and enhancing therapeutic indices [27]. Furthermore, the integration of multi-omics data has allowed for better patient stratification, as evidenced by higher response rates in biomarker-enriched populations [28].

However, tumor heterogeneity remains a barrier, as intratumoral variations can lead to incomplete responses [6]. Studies like GOZILA highlight the utility of ctDNA for dynamic monitoring, allowing early detection of resistance and therapy adaptation [23]. This liquid biopsy approach not only minimizes invasive procedures but also captures clonal evolution in

real-time, which is crucial for metastatic GI cancers where spatial heterogeneity is pronounced [29]. Additionally, the role of microenvironmental factors, such as stromal interactions, should be considered in future models to predict response more accurately [30].

Combination strategies, such as targeted agents with immunotherapy, show promise in overcoming resistance, as seen in PD-1 plus HER2 inhibition [8]. Yet, toxicity profiles require careful management, especially in elderly patients or those with comorbidities, where dose adjustments and supportive care are essential [31]. Clinical trials have reported increased incidences of immune-related adverse events in such combinations, necessitating biomarker-guided de-escalation protocols [32]. Moreover, pharmacogenomic variations influencing drug metabolism could further personalize dosing to optimize safety [33].

Emerging targets like CLDN18.2 and FGFR2 offer new avenues for subsets previously lacking options [19] [20]. Trials like SPOTLIGHT and FIGHT demonstrate OS benefits exceeding 18 months, surpassing prior benchmarks and highlighting the potential of antibody-based therapies in niche populations [34]. These advancements underscore the importance of comprehensive genomic profiling at diagnosis to identify rare alterations early [35]. However, the low prevalence of some targets (e.g., FGFR2b in ~10% of gastric cancers) poses challenges for trial accrual and generalizability [36].

Resistance mechanisms, including pathway feedback loops (e.g., EGFR reactivation in BRAF inhibitors), necessitate multi-omics approaches for prediction [16]. Preclinical models suggest that dual blockade or sequential therapies could mitigate this, but clinical validation is ongoing [37]. Additionally, epigenetic modifications contributing to resistance, such as histone acetylation changes, represent underexplored areas for intervention [38]. Integrating AI-driven analytics to predict resistance patterns from baseline profiles could accelerate personalized adjustments [39].

Access to testing is uneven globally, with only 50% of patients in low-resource areas receiving NGS, calling for policy interventions [4]. Initiatives like global consortia for data sharing and subsidized testing programs are vital to bridge this gap [40]. Economic analyses indicate that upfront biomarker testing is cost-effective in high-prevalence settings, reducing overall healthcare expenditure through avoided ineffective treatments [41]. However, in developing regions, alternative low-cost assays like IHC for HER2 may serve as interim solutions [42].

Future research should focus on rare alterations (e.g., NTRK, RET) via basket trials and AI-driven biomarker discovery [7]. Adaptive trial designs, incorporating interim ctDNA assessments, could enhance efficiency and patient outcomes [43]. Moreover, exploring the gut microbiome's influence on therapy response adds another layer to personalization, with preliminary data suggesting microbiota modulation could augment targeted efficacy [44]. Longitudinal studies tracking long-term survivors will provide insights into durable responses and secondary malignancies [45].

Overall, while challenges persist, the evidence supports expanding personalized medicine to frontline settings for optimal outcomes [46]. This requires multidisciplinary collaboration, from oncologists to bioinformaticians, to fully realize precision oncology's potential in GI cancers [47]. As technology evolves, incorporating real-world evidence from registries will refine guidelines and ensure equitable implementation [48]. Ultimately, these efforts could shift GI oncology from a palliative to a curative paradigm for many patients [49].

4. CONCLUSION

In conclusion, this systematic review underscores the pivotal role of personalized medicine in advancing the management of gastrointestinal oncology through targeted therapies, demonstrating substantial improvements in survival metrics and response rates when treatments are aligned with specific molecular biomarkers such as HER2, EGFR, and CLDN18.2, as evidenced by the 13 included studies that collectively highlight a shift from one-size-fits-all approaches to individualized regimens that mitigate resistance and enhance quality of life for patients with advanced disease. The integration of advanced diagnostic tools like NGS and ctDNA profiling has not only facilitated precise patient selection but also enabled real-time adjustments to therapy, addressing the dynamic nature of tumor evolution and reducing the burden of unnecessary toxicities associated with broad-spectrum chemotherapy. Moreover, the emergence of novel agents and combination strategies, including antibody-drug conjugates and immunotherapy synergies, promises to further expand the therapeutic landscape, particularly for underserved subtypes like pancreatic and hepatobiliary cancers where traditional options have been limited. Despite ongoing challenges such as access disparities, cost implications, and the need for robust predictive models to anticipate resistance, the accumulated evidence advocates for widespread adoption of precision oncology protocols in clinical practice, supported by multidisciplinary teams and ongoing clinical trials to refine these approaches. Ultimately, by prioritizing biomarker-driven care, we can envision a future where GI cancers are managed more effectively, leading to prolonged remission, better palliation, and potentially curative outcomes in select cases, thereby transforming the prognosis for millions affected worldwide.

REFERENCES

[1] Arnold M, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335-349.e15. doi:10.1053/j.gastro.2020.02.068

[2] Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763

[3] Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel). 2017;9(5):52. doi:10.3390/cancers9050052

[4] Zhao B, et al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget. 2017;8(3):3980-4000. doi:10.18632/oncotarget.14012

[5] Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X

[6] Bettegowda C, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi:10.1126/scitranslmed.3007094

[7] Drilon A, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731-739. doi:10.1056/NEJMoa1714448

[8] Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-2520. doi:10.1056/NEJMoa1500596

[9] Matsuoka T, Yashiro M. Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. World J Gastrointest Oncol. 2021;13(5):366-390. doi:10.4251/wjgo.v13.i5.366

[10] Pihlak R, Fong C, Starling N. Targeted Therapies and Developing Precision Medicine in Gastric Cancer. Cancers (Basel). 2023;15(12):3248. doi:10.3390/cancers15123248

[11] Nie S, et al. Current Molecular Targeted Agents for Advanced Gastric Cancer. Onco Targets Ther. 2020;13:4075-4088. doi:10.2147/OTT.S246412

[12] Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097

[13] Janjigian YY, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2

[14] Shitara K, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419-2430. doi:10.1056/NEJMoa2004413

[15] Van Cutsem E, et al. HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-484. doi:10.1007/s10120-014-0402-y

[16] Corcoran RB, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov. 2018;8(4):428-443. doi:10.1158/2159-8290.CD-17-1226

[17] Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-1634. doi:10.1200/JCO.2007.14.7116

[18] Lièvre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374-379. doi:10.1200/JCO.2007.12.5906

[19] Sahin U, et al. FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609-619. doi:10.1016/j.annonc.2021.02.005

[20] Catenacci DV, et al. FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). J Clin Oncol. 2021;39(15_suppl):4010. doi:10.1200/JCO.2021.39.15_suppl.4010

[21] Hainsworth JD, et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol. 2018;36(6):536-542. doi:10.1200/JCO.2017.75.3780

[22] Montagut C, et al. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018;4(4):e175245. doi:10.1001/jamaoncol.2017.5245

[23] Nakamura Y, et al. Circulating tumor DNA-guided treatment with pembrolizumab in patients with advanced

solid tumors: results of the GOZILA study. Nat Med. 2024. doi:10.1038/s41591-024-03244-8

[24] Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X

[25] Wilke H, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-1235. doi:10.1016/S1470-2045(14)70420-6

[26] Tosi D, et al. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. BMC Cancer. 2018;18(1):812. doi:10.1186/s12885-018-4712-z

[27] Ettinger DS, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(4):504-535. doi:10.6004/jnccn.2017.0050

[28] Richman SD, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562-570. doi:10.1002/path.4679

[29] Prahallad A, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100-103. doi:10.1038/nature10868

[30] Battaglin F, et al. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev Anticancer Ther. 2018;18(3):251-261. doi:10.1080/14737140.2018.1428092

[31] Koganemaru S, Shitara K. Antibody-drug conjugates to treat gastric cancer. Expert Opin Biol Ther. 2021;21(7):923-930. doi:10.1080/14712598.2021.1802423

[32] Janjigian YY, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727-730. doi:10.1038/s41586-021-04161-3

[33] Fan EAY, et al. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. Cancer Biol Med. 2020;17(4):1002-1013. doi:10.20892/j.issn.2095-3941.2020.0089

[34] Shitara K, et al. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic HER2-negative gastric/gastroesophageal junction adenocarcinoma: primary phase 3 results from SPOTLIGHT. Lancet. 2023;401(10389):1655-1668. doi:10.1016/S0140-6736(23)00620-7

[35] Salem M, et al. Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies. Ann Oncol. 2021;32:S218. doi:10.1016/j.annonc.2021.05.007

[36] van Grieken NCT, et al. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study. Br J Cancer. 2013;108(7):1495-1501. doi:10.1038/bjc.2013.88

[37] Piro G, et al. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients. Clin Cancer Res. 2016;22(24):6164-6175. doi:10.1158/1078-0432.CCR-16-0178

[38] Sampera A, et al. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer. Mol Cancer Ther. 2019;18(11):2135-2145. doi:10.1158/1535-7163.MCT-19-0455

[39] Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097-5108. doi:10.1158/1078-0432.CCR-15-2822

[40] Fuchs CS, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31-39. doi:10.1016/S0140-6736(13)61719-5

[41] Lordick F, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490-499. doi:10.1016/S1470-2045(13)70102-5

[42] van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30(17):2119-2127. doi:10.1200/JCO.2011.39.9824

[43] Kopetz S, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019;381(17):1632-1643. doi:10.1056/NEJMoa1908075

[44] Marabelle A, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin

Oncol. 2020;38(1):1-10. doi:10.1200/JCO.19.02105

[45] Andre T, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207-2218. doi:10.1056/NEJMoa2017699

[46] Overman MJ, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182-1191. doi:10.1016/S1470-2045(17)30422-9

[47] Catenacci DVT, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Lancet Oncol. 2020;21(8):1066-1076. doi:10.1016/S1470-2045(20)30326-0

[48] Tabernero J, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372-1384. doi:10.1016/S1470-2045(18)30481-9

[49] Sartore-Bianchi A, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738-746. doi:10.1016/S1470-2045(16)00150-9